Lilly Humatrope for short stature
Executive Summary
Lilly's Humatrope (somatropin rDNA origin) supplemental NDA (19-604/S-033) for treatment of non-growth hormone deficiency short stature will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on June 10. Studies have shown that growth hormone treatment in children with idiopathic short stature and normal GH levels may increase height by 4-6 cm over controls. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m...